艾迪注射液联合化疗治疗晚期肺癌临床疗效及对炎性因子、免疫功能的影响  

Clinical Curative Effect of Aidi Injection Combined with Chemotherapy on Advanced Lung Cancer and Its Influences on Inflammatory Factors and Immune Function

作　　者：张志红[1] 倪秉强[1] 陈日新[1] 李竟长[1] 朱州[1] 卫青青 覃振哲 秦佳宁[1] ZHANG Zhihong;NI Bingqiang;CHEN Rixin;LI Jingchang;ZHU Zhou;WEI Qingqing;QIN Zhenzhe;QIN Jianing(Liuzhou People's Hospital of Guangxi Zhuang Autonomous Region,Liuzhou 545006)

机构地区：[1]广西壮族自治区柳州市人民医院,广西柳州545006

出　　处：《湖北中医药大学学报》2020年第6期17-20,共4页Journal of Hubei University of Chinese Medicine

基　　金：广西壮族自治区柳州市社会卫生计划科研项目(项目编号:LZ2017A131)。

摘　　要：目的观察艾迪注射液联合多西他赛、顺铂治疗晚期肺癌临床疗效及对炎性因子与免疫功能的影响。方法将本院90例晚期肺癌患者随机分为观察组与对照组各45例。对照组采用多西他赛联合顺铂方案化疗,观察组在对照组治疗基础上联合艾迪注射液治疗。比较两组临床疗效、炎性因子水平、免疫功能、不良反应情况。结果观察组临床疗效与对照组相比无差异(P>0.05)。治疗后,观察组肿瘤坏死因子-α(TNF-α)、干扰素-α(INF-α)、白细胞介素-2(IL-2)、CD8^(+)水平均低于对照组;观察组CD3^(+)、CD4^(+)、CD4^(+)/CD8^(+)、自然杀伤细胞(NK)、免疫球蛋白(IgA、IgG、IgM)水平均高于对照组(P<0.05);观察组呕吐、白细胞减少、乏力不良反应发生率低于对照组(P<0.05);化疗结束3个月后,观察组生活质量改善率优于对照组(P<0.05)。结论艾迪注射液联合多西他赛及顺铂化疗治疗晚期肺癌患者,可有效调节免疫功能,改善血清炎性因子水平并减少不良反应的发生,提高生活质量。Objective To observe the clinical curative effect of Aidi Injection combined with docetaxel and cisplatin on patients with advanced lung cancer and its influences on inflammatory factors and immune function. Methods A total of 90 patients with advanced lung cancer were randomly divided into control group(docetaxel combined with cisplatin for chemotherapy)and experimental group(Aidi Injection on the basis of control group). The curative effect,levels of inflammatory factors,immune function and adverse reactions were compared between the two groups. Results There was no difference in clinical efficacy between experimental group and control group( P>0.05). After chemotherapy,the levels of tumor necrosis factor-α(TNF-α),interferon-α(INF-α),interleukin-2(IL-2)and CD8^(+)in experimental group were lower than those in control group,while the levels of CD4^(+),CD4^(+),CD4^(+)/CD8^(+),natural killer cells(NK),immunoglobulin A(Ig A),Ig G and Ig M were higher than those in control group( P<0.05);the incidence of adverse reactions(vomiting,leukopenia,fatigue)in experimental group was lower than that in control group( <0.05);three months after chemotherapy,the improvement rate of quality of life in experimental group was better than that in control group( P<0.05). Conclusion Aidi Injection combined with docetaxel and cisplatin for chemotherapy can effectively regulate immune function,improve the levels of serum inflammatory factors,reduce the occurrence of adverse reactions,and improve the quality of life of patients with advanced lung cancer.

关 键 词：晚期肺癌 免疫球蛋白 艾迪注射液 T细胞亚群 炎性因子 

分 类 号：R259[医药卫生—中西医结合]